RxDoctor Payments DataLook up a doctor →

Ronald Leo, MD

Gastroenterology · Baton Rouge, LANPI 1295700623

Payments from drug & device makers

$90,881in general payments, 2019–2025

Across 410 payments — averaging $221.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$61K
  • Apollo Endosurgery US Inc$21K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • AbbVie$2K
  • Bristol Myers Squibb$505
  • Johnson & Johnson$483
  • plus $3K from 31 others

What the payments were for

  • Speaking & faculty fees$3,00033%
  • Food & beverage$6,07467%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,881 in reported general payments places this provider in the 85th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$170,244
Medicare patients
403
Services billed
5,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab28$883,346
CreonLipase/Protease/Amylase64$109,604
Humira PenAdalimumab11$71,824
LinzessLinaclotide79$55,271
ZenpepLipase/Protease/Amylase24$39,926
ClenpiqSod Picosulf/Mag Ox/Citric Ac85$13,946
Pantoprazole Sodium672$11,350
TrulancePlecanatide13$9,945
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates131$8,683
Mesalamine ErMesalamine17$6,289
Dexlansoprazole DrDexlansoprazole15$4,342
Sucralfate142$3,902
Ursodiol30$3,208
Dicyclomine Hcl174$2,633
Colestipol Hcl50$2,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$483$883,34628 claims
AbbVieCreon, Linzess$1,802$164,875143 claims
Aimmune Therapeutics, Inc.Zenpep$19$39,92624 claims
Ferring Pharmaceuticals Inc.Clenpiq$112$13,94685 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$3,301$9,94513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →